AllianceBernstein
CYCN icon

AllianceBernstein’s Cyclerion Therapeutics CYCN Stock Holding History

AllianceBernstein’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,590
Closed -$89K – 3348
2021
Q1 		$89K Hold
1,590
– – ﹤0.01% 3168
2020
Q4 		$97K Sell
1,590
-111
-7% -$7.57K ﹤0.01% 3104
2020
Q3 		$207K Sell
1,701
-88
-5% -$10.1K ﹤0.01% 2952
2020
Q2 		$211K Buy
1,789
+371
+26% +$31K ﹤0.01% 2994
2020
Q1 		$75K Hold
1,418
– – ﹤0.01% 3009
2019
Q4 		$77K Hold
1,418
– – ﹤0.01% 3067
2019
Q3 		$344K Buy
1,418
+175
+14% +$37.8K ﹤0.01% 2744
2019
Q2 		$285K Buy
+1,243
New +$352K ﹤0.01% 2847

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AllianceBernstein's CYCN Position: Q2 2021 in Review

AllianceBernstein sold out of Cyclerion Therapeutics (CYCN) in Q2 2021, closing a stake of 1,590 shares — an estimated $89K sold.

AllianceBernstein first reported a position in CYCN in Q2 2019 and held it in 8 quarters. The position peaked at $344K in Q3 2019. 67 funds tracked by Wall St. Rank hold CYCN as of Q2 2021.

  • AllianceBernstein reported no remaining Cyclerion Therapeutics position as of Q2 2021 after selling out during the quarter.
  • AllianceBernstein sold 1,590 Cyclerion Therapeutics shares in Q2 2021, an estimated $89K.
  • AllianceBernstein first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 8 quarters.
  • AllianceBernstein's Cyclerion Therapeutics position peaked at $344K in Q3 2019.
  • 67 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2021.

Based on AllianceBernstein's 13F filing for Q2 2021, filed 30 Jul 2021.